| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Helicobacter pylori: High dose amoxicillin does not improve primary or secondary eradication rates in an Irish cohort
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Conor Costigan, Aoife M O'Sullivan, Jim O'Connell, Shreyashee Sengupta, Thomas Butler, Stephen Molloy, Fintan John O'Hara, Barbara Ryan, Niall Breslin, Sarah O'Donnell, Anthony O'Connor, Sinead Smith and Deirdre McNamara |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Conor Costigan, BM BCh, Assistant Professor, Doctor, Doctor, Lecturer, Trinity Academic Gastroenterology Group, School of Medicine-Trinity College Dublin, Centre for Learning and Development
Tallaght University Hospital
Dublin 24, Dublin D2, Ireland. conorcostigan92@gmail.com |
| Key Words |
Helicobacter pylori eradication; Helicobacter pylori; High dose amoxicillin; High dose amoxicillin dual therapy; Triple therapy |
| Core Tip |
We present a prospective assessment of high dose amoxicillin dual therapy (HDADT) for Helicobacter pylori in an Irish cohort. Ireland is a 'high dual-resistance country'-(clarithromycin and metronidazole)-mainstays of traditional treatment. Where bismuth-based therapy is unavailable, as in Ireland, European guidelines recommend HDADT can be considered. This is the first data on HDADT to date in Ireland, and despite promising data from Asia, European data remains scant. Our results show disappointing eradication rates; we discuss possible reasons why and provide clinical evidence to authorities for the need to make bismuth-therapy available in our country. We advise against HDADT in European populations. |
| Publish Date |
2024-05-29 12:34 |
| Citation |
Costigan C, O'Sullivan AM, O'Connell J, Sengupta S, Butler T, Molloy S, O'Hara FJ, Ryan B, Breslin N, O'Donnell S, O'Connor A, Smith S, McNamara D. Helicobacter pylori: High dose amoxicillin does not improve primary or secondary eradication rates in an Irish cohort. World J Clin Cases 2024; 12(16): 2773-2779 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i16/2773.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i16.2773 |
